CRB Group, a pharma engineering consultant, notes that short-term capacity additions (e.g
The novel GLP-1 and amylin receptor agonist amycretin appears to be safe and tolerable and results in significant reductions in body weight in individuals with overweight or obesity, according to research published in The Lancet
J Clin Invest 98 :136141
For many patients with obesity, particularly those with related health conditions such as type 2 diabetes, cardiovascular disease, or obstructive sleep apnoea, GLP-1 medications offer significant health benefits that extend beyond weight reduction
But for women managing chronic migraine alongside obesity or metabolic conditions, this is a clinically meaningful overlap worth raising with a provider
Exercise and Sport Sciences Reviews, 45 (3), 136145